Suzhou Immunofoco Biotechnology Co., Ltd
Suzhou Immunofoco Biotechnology Co., Ltd
Explore linked clinical trials.5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Dose-Escalation/Expansion Study of iMagic in Relapsed/Refractory Hematologic Malignancies | Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Not yet recruiting | Early phase 1 | 2026-09-08 | NCT07802756 | |
| A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Early phase 1 | 2026-09-03 | NCT07493135 | |
| Phase I/IIa Clinical Trial of IMC001 in Patients With Advanced Epithelial Solid Tumors. | Epithelial Cancer Patients | Enrolling by invitation | Phase 1 / Phase 2 | 2026-06-12 | NCT07644403 | |
| A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Early phase 1 | 2026-03-30 | NCT07376642 | |
| A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients | gastric adenocarcinoma | Recruiting | Phase 3 | 2025-10-23 | NCT07103668 |